In particular, three independent studies of breast cancer patient cohorts have recently reported recurrent somatic mutations and/or deletions of RUNX1, as well as CBFB that encodes an obligate co-activator of RUNX1 (refs 18, 19, 20). Here, RUNX1 is linked to breast carcinoma.